Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer

Johnson, Renjith P.; Ratnacaram, Chandrahas Koumar; Kumar, Lalit; Jose, Jobin

doi:10.1016/j.drup.2022.100865

Cited by 9 publications

(6 citation statements)

References 422 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, tumor immunity is the basis of tumor radiotherapy, and the mechanism of the body's immune response to tumors and the escape of tumor cells from the immune effect greatly determines how to investigate new tumor treatment options [ 33 , 34 ]. As mentioned in a previous study, allicin can be used to treat arthritis by modulating immune homeostasis in arthritic mice [ 35 ], so we hypothesized that allicin might have the same effect on OS.…”

Section: Discussionmentioning

confidence: 99%

Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1

Xie,

Ma,

Dou

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1

Xie,

Ma,

Dou

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…With that in mind, combining polyphenol-based bioactive compounds and anticancer drugs may offer a potential synergistic approach to cancer therapy [ 158 ]. Thus, polyphenol–drug delivery systems have lately been designed to increase the effectiveness of anticancer drugs by improving their delivery to tumor cells and minimizing their distribution to healthy tissues, thus reducing the drug side effects [ 159 ].…”

Section: Application Of Nanotechnology Improving the Efficiency Of Po...mentioning

confidence: 99%

Recent Progress in Nanotechnology Improving the Therapeutic Potential of Polyphenols for Cancer

Vieira,

Tessaro,

Lima

et al. 2023

Nutrients

View full text Add to dashboard Cite

Polyphenols derived from fruits, vegetables, and plants are bioactive compounds potentially beneficial to human health. Notably, compounds such as quercetin, curcumin, epigallocatechin-3-gallate (EGCG), and resveratrol have been highlighted as antiproliferative agents for cancer. Due to their low solubility and limited bioavailability, some alternative nanotechnologies have been applied to encapsulate these compounds, aiming to improve their efficacy against cancer. In this comprehensive review, we evaluate the main nanotechnology approaches to improve the therapeutic potential of polyphenols against cancer using in vitro studies and in vivo preclinical models, highlighting recent advancements in the field. It was found that polymeric nanomaterials, lipid-based nanomaterials, inorganic nanomaterials, and carbon-based nanomaterials are the most used classes of nanocarriers for encapsulating polyphenols. These delivery systems exhibit enhanced antitumor activity and pro-apoptotic effects, particularly against breast, lung, prostate, cervical, and colorectal cancer cells, surpassing the performance of free bioactive compounds. Preclinical trials in xenograft animal models have revealed decreased tumor growth after treatment with polyphenol-loaded delivery systems. Moreover, the interaction of polyphenol co-delivery systems and polyphenol–drug delivery systems is a promising approach to increase anticancer activity and decrease chemotherapy side effects. These innovative approaches hold significant implications for the advancement of clinical cancer research.

show abstract

“…Mechanically, a few essential factors or products of lipid peroxidation metabolism, such as solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase (GPX4), glutathione (GSH), and malondialdehyde (MDA), are related to ferroptosis [4]. Considering that PCa with metastatic potential [5] and cancer cells with metastatic and invasive abilities are susceptible to ferroptosis [6], we hypothesized that targeting certain ferroptosis-related genes (FRGs) may be useful in treating PCa. An increasing number of researchers have focused on the relationship between ferroptosis and PCa.…”

Section: Introductionmentioning

confidence: 99%

Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure

Wu,

Huang,

Jiang

et al. 2024

BMC Urol

View full text Add to dashboard Cite

Background Few studies are focusing on the mechanism of erastin acts on prostate cancer (PCa) cells, and essential ferroptosis-related genes (FRGs) that can be PCa therapeutic targets are rarely known. Methods In this study, in vitro assays were performed and RNA-sequencing was used to measure the expression of differentially expressed genes (DEGs) in erastin-induced PCa cells. A series of bioinformatic analyses were applied to analyze the pathways and DEGs. Results Erastin inhibited the expression of SLC7A11 and cell survivability in LNCaP and PC3 cells. After treatment with erastin, the concentrations of malondialdehyde (MDA) and Fe2+ significantly increased, whereas the glutathione (GSH) and the oxidized glutathione (GSSG) significantly decreased in both cells. A total of 295 overlapping DEGs were identified under erastin exposure and significantly enriched in several pathways, including DNA replication and cell cycle. The percentage of LNCaP and PC3 cells in G1 phase was markedly increased in response to erastin treatment. For four hub FRGs, TMEFF2 was higher in PCa tissue and the expression levels of NRXN3, CLU, and UNC5B were lower in PCa tissue. The expression levels of SLC7A11 and cell survivability were inhibited after the knockdown of TMEFF2 in androgen-dependent cell lines (LNCaP and VCaP) but not in androgen-independent cell lines (PC3 and C4-2). The concentration of Fe2+ only significantly increased in TMEFF2 downregulated LNCaP and VCaP cells. Conclusion TMEFF2 might be likely to develop into a potential ferroptosis target in PCa and this study extends our understanding of the molecular mechanism involved in erastin-affected PCa cells.

show abstract

Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer

Cited by 9 publications

References 422 publications

Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1

Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1

Recent Progress in Nanotechnology Improving the Therapeutic Potential of Polyphenols for Cancer

Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure

Contact Info

Product

Resources

About